Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Intravenous gammaglobulin
100%
Acute Pain
100%
Vaso-occlusion
100%
Sickle Cell Disease
100%
Phase 1/2 Clinical Trial
100%
Acute Pain Episodes
50%
Endothelium
50%
Narcotic Use
33%
Leukocytes
33%
Phase 3 Trial
16%
Randomized Double-blind
16%
Serum Markers
16%
Standard of Care
16%
Leukocyte Adhesion
16%
Hemoglobinopathies
16%
Physiological Effects
16%
Latino
16%
Dose Escalation
16%
Blood Serum
16%
Molecular Mechanism
16%
Placebo-controlled
16%
Pain Score
16%
Flow Markers
16%
Blood Vessels
16%
Normal Saline
16%
Length of Hospital Stay
16%
Adhesion Receptors
16%
Hospitalization
16%
National Institutes of Health
16%
African American
16%
Red Blood Cells
16%
State Affect
16%
Clinical Complications
16%
Health Applications
16%
Patient-specific Treatment
16%
Placebo
16%
Cell Interaction
16%
Sickle Red Blood Cells
16%
United States
16%
Leukocyte Adherence
16%
Small Vessel Occlusion
16%
Microvascular Blood Flow
16%
Red Cells
16%
Mouse Model
16%
Medicine and Dentistry
Human Immunoglobulin
100%
Sickle Cell
100%
Pain
100%
Immunoglobulin
100%
Endothelium
75%
Erythrocyte
50%
Leukocyte Adherence
50%
Leukocyte
50%
Placebo
50%
Hemolysis
25%
Hemoglobinopathy
25%
Diseases
25%
Adhesion Receptor
25%
Cell Interaction
25%
Sickle-Cell Disease
25%
Blood Flow
25%
Single Drug Dose
25%
Vascular Bundle
25%
Table Salt
25%
Pharmacology, Toxicology and Pharmaceutical Science
Human Immunoglobulin
100%
Pain
100%
Immunoglobulin
100%
Narcotic Agent
50%
Placebo
50%
Hemolysis
25%
Hemoglobinopathy
25%
Mouse Model
25%
Receptor
25%
Sickle Cell Anemia
25%
Table Salt
25%
Diseases
25%